Table of contents

Electronic pages

• Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” (13 August, 2021)

  Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
• Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by van Vollenhoven et al

  (13 August, 2021)

  Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
• Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ (22 November, 2021)

  Yudong Liu
• Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Liu (22 November, 2021)

  Marvin J Fritzler, Uriel Trahtemberg
• Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’ (19 August, 2020)

  Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini
• Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’ (21 September, 2020)

  Martin Sebastian Winkler, Peter Korsten, Claudia Binder, Björn Tampe
• Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment’ (17 February, 2022)

  Ricardo J O Ferreira, Paco M J Welsing, Johannes WG Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M Machado, Désirée van der Heijde, Jose AP Da Silva
• Response to: Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment’ by Ferreira et al

  (17 February, 2022)

  David Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha
• Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ (29 November, 2021)

  Stefan Siebert, Helena Marzo-Ortega
• Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physicianreported spondylitis’?’ by Siebert and Marzo-Ortega (29 November, 2021)

  Juergen Braun, Robert BM Landewé
• Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ (29 April, 2022)

  Dafna D Gladman, Philip J Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, Xenofon Baraliakos
• Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman (29 April, 2022)

  Robert BM Landewé, Juergen Braun
• Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” (3 August, 2021)

  Guillermo J Pons-Estel, Manuel F. Ugarte-Gil, Guillermina B Harvey, Bernardo A Pons-Estel, Graciela S Alarcón
• Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Pons-Estel et al

  (3 August, 2021)

  Laura Whittall-Garcia, Dafna D Gladman, Murray Urowitz, Jiandong Su, Zahi Touma, Sindhu R Johnson
• Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” (3 August, 2021)

  Zhuochao Zhou, Yijun You, Fan Wang, Yue Sun, Jialin Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Chengde Yang, Junna Ye
• Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Zhou et al

  (3 August, 2021)

  Antonis Fanouriakis, Nikolaos Tziolos, George Bertsias, Dimitrios T Boumpas
• Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” (11 September, 2021)

  Xavier Bossuyt, Walter Fierz, Pier Luigi Meroni
• Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Bossuyt et al

  (11 September, 2021)

  Martin Aringer, Karen Costenbader, Nicolai Leuchten, Thomas Dörner, Sindhu R Johnson
• Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ (13 January, 2022)

  Dimitrios Patoulias
• Response to: Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ by Patoulias (13 January, 2022)

  Marcus Säemann, Andreas Kronbichler
• Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’

  (22 March, 2022)

  Victor Román Pimentel-Quiroz, Manuel Francisco Ugarte-Gil, Graciela S Alarcón
• Response to: Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’ by Pimentel-Quiroz et al

  (22 March, 2022)

  Peter C Grayson, Joanna C Robson, Ravi Suppiah, Cristina Ponte, Richard A Watts, Raashid A Luqmani, Peter A Merkel
• Where are the women ‘Heroes and Pillars of Rheumatology’? (4 February, 2022)

  Nicola Dalbeth, Tuhina Neogi
• Response to: Where are the women ‘Heroes and Pillars of Rheumatology’? (4 February, 2022)

  Josef S Smolen